112 related articles for article (PubMed ID: 15609197)
1. Health care reform in six Central European countries. A focus on health economic requirements in the drug pricing and reimbursement processes.
Nuijten MJ; Szende A; Kosa J; Mogyorosy Z; Kramberger B; Nemecek K; Tomek D; Oreskovic S; Laskowska M
Eur J Health Econ; 2003 Nov; 4(4):286-91. PubMed ID: 15609197
[TBL] [Abstract][Full Text] [Related]
2. Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation.
Füredi J; Mohr P; Swingler D; Bitter I; Gheorghe MD; Hotujac L; Jarema M; Kocmur M; Koychev GI; Mosolov SN; Pecenak J; Rybakowski J; Svestka J; Sartorius N
Acta Psychiatr Scand; 2006 Oct; 114(4):223-31. PubMed ID: 16968359
[TBL] [Abstract][Full Text] [Related]
3. E-health development policies in new member states in Central Europe.
Duplaga M
World Hosp Health Serv; 2007; 43(2):34-8. PubMed ID: 17894192
[TBL] [Abstract][Full Text] [Related]
4. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
5. Pricing and reimbursement of drugs in Sweden.
Lundkvist J
Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
[TBL] [Abstract][Full Text] [Related]
6. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
[No Abstract] [Full Text] [Related]
8. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
9. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
Anell A; Persson U
Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
[TBL] [Abstract][Full Text] [Related]
10. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
11. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
Kolasa K; Kalo Z; Zah V; Dolezal T
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
[TBL] [Abstract][Full Text] [Related]
12. Health economic research on vaccinations and immunisation practices--an introductory primer.
Szucs TD
Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
[TBL] [Abstract][Full Text] [Related]
13. Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries.
Skoupá J; Annemans L; Hájek P
Value Health Reg Issues; 2014 Sep; 4():53-57. PubMed ID: 29702807
[TBL] [Abstract][Full Text] [Related]
14. Differences in external price referencing in Europe: a descriptive overview.
Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
[TBL] [Abstract][Full Text] [Related]
15. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
Rubinstein A; Pichon-Riviere A; Augustovski F
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
[TBL] [Abstract][Full Text] [Related]
16. The costs and benefits of regulations for reimbursement of new drugs.
Lundkvist J; Jönsson B; Rehnberg C
Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
[TBL] [Abstract][Full Text] [Related]
17. Current status of epilepsy health care for adult patients from central and eastern European Union countries--a survey of members of the Central Europe Epilepsy Experts Working Group.
Jędrzejczak J; Marusic P; Haldre S; Majkowska-Zwolińska B; Bojinova-Tchamova V; Mameniskiene R; Mindruta I; Ravnik IM; Szupera Z; Sykora P; Verzbickis A; Daniluk J
Seizure; 2013 Jul; 22(6):452-6. PubMed ID: 23528980
[TBL] [Abstract][Full Text] [Related]
18. Pricing and reimbursement of drugs in Denmark.
Møller Pedersen K
Eur J Health Econ; 2003; 4(1):60-5. PubMed ID: 15609170
[TBL] [Abstract][Full Text] [Related]
19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical pricing and reimbursement reforms in Greece.
Yfantopoulos J
Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
